Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 5/20 | 0.49 |
| ▸ | BACE1 | P56817 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18886212 | 0.89 | GPR119 (0.46) | CTSDBACE1GPR119AKT1SYK | |
| SCHEMBL6680422 | 0.76 | AKT1 (0.39) | CTSDBACE1AKT1CNR1CNR2 | |
| SCHEMBL2036519 | 0.76 | CTSB (0.40) | BACE1AKT1CNR1CNR2KIT | |
| SCHEMBL31360210 | 0.76 | CTSB (0.40) | BACE1AKT1CNR1CNR2KIT | |
| SCHEMBL27425997 | 0.76 | DRD2 (0.40) | AKT1CNR1CNR2KIT | |
| SCHEMBL4404243 | 0.75 | LMNA (0.54) | LMNAKDM4EMAPK1 | |
| SCHEMBL2554955 | 0.75 | AKT1 (0.47) | AKT1CNR1CNR2KDM4E | |
| SCHEMBL25155496 | 0.75 | CNR1 (0.42) | AKT1CNR1CNR2 | |
| SCHEMBL30344050 | 0.75 | CNR1 (0.42) | AKT1CNR1CNR2 | |
| SCHEMBL27426505 | 0.75 | AKT1 (0.40) | CTSDBACE1AKT1CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430920-B1 | Substituted benzene fungicides | DU PONT (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-1937638-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007047306-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007047306-A1 | METHODS OF TREATING AMYLOIDOSIS USING ARYL-CYCLOPROPYL DERIVATIVE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149525-A1 | Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors | APP, DNPEP, ASPH | CTSD 51/4885BACE1 5/4885LMNA 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.